

Newsletter



Intoinworld

Intoinworld Co., Ltd., a people-focused company.

"From people to people, connecting the value of clinical research."

Intoinworld Co., Ltd. strives to be a bridge of trust between patients, investigators, and sponsors, ensuring that the value of medical innovation is safely delivered to people. Founded in 2015, we are a contract research organization (CRO) that conducts diverse clinical studies across pharmaceuticals, biotechnology, medical devices, investigator-initiated trials (IITs) and observational studies, guided by a people-centered mindset.



Korean biosimilars gear up for wave of blockbuster patent expiries

~200 drugs lose exclusivity by 2030, including ~70 blockbusters, fueling a Korean biosimilar race. Developers yckopate trials and patent settlements for first-mover launches, while originators use evergreening and new formulations (e.g., subcutaneous switches) to delay competition.

MFDS bets on early intervention to cut rare disease drug delays

MFDS is rolling out a full-cycle framework for rare disease drugs, linking early regulatory alignment, more flexible orphan designation, and expedited/priority reviews. The aim is to cut trial-and-error with limited patient data, speed approvals (sometimes on phase 2 evidence with post-approval data), and shift regulators from gatekeepers to development partners.



In the Alzheimer's market, Big Pharma's focus shifts from drugs to technological value.

Alzheimer's R&D is shifting to disease-modifying therapies and multi-target approaches, with BBB delivery platforms becoming a core battleground. Dealmaking is moving from late-stage assets to early-stage platforms and package deals, with more milestone-based payments to share risk.



www.intoinworld.com



bd@intoinworld.kr



+82 02-515-8082



Medical AI adoption blocked by high-efficiency systems... A national, low-cost model is the answer.

A report urges scalable AI platforms, low-cost small language models, and national cloud/GPU infrastructure to speed adoption. A pilot using on-premise sLLMs cut discharge documentation time 66% and burden 37%. Government will fund AI treatment systems across 17 hospitals nationwide.

Depression Treatment with 'Electro-Pills'... The Customized Treatment Market Grows

Korea's depression digital therapeutics market is expanding as approvals and prescription-based RWE grow. A new app was designated an innovative device, joining two existing options. Adoption is rising, with large prescription volumes and trial data suggesting meaningful symptom improvement, supporting non-drug, home-based, personalized care alongside medication.



Strengthening early precancerous screening and precision diagnosis... Expanding AI-based cancer research.

Korea's 2026–2030 cancer plan will boost research on precancerous biomarkers and liquid biopsy, while supporting advanced targeted therapies like CGT/CAR-T. It also aims to build response/resistance prediction platforms, expand multimodal cancer data, develop a cancer AI foundation model, and strengthen clinical research networks to speed translation into care.

